StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report released on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
Shares of NASDAQ:BLPH opened at $0.01 on Wednesday. Bellerophon Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.02. The company has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The company has a fifty day moving average of $0.04 and a 200-day moving average of $0.04.
Bellerophon Therapeutics Announces Dividend
The company also recently announced a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a $0.019 dividend. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- What is the FTSE 100 index?
- Stock Buybacks Outperform Dividends: Here’s the Key Advantage
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- 3 Warren Buffett Stocks to Buy Now
- Why Now Is the Ultimate Time to Invest in Oil Stocks
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
